Advertisement

Zytostatika und Immunsuppressiva

  • E. Oberdisse
Part of the Springer-Lehrbuch book series (SLB)

Zusammenfassung

Die therapeutische Anwendung heute gebräuchlicher Zytostatika beruht auf der (nicht immer zutreffenden) Annahme, daß Tumoren eine höhere Zellteilungsrate bzw. eine kürzere Zellgenerationszeit als normales Gewebe aufweisen. Die Kenntnis des Zellzyklus ist daher zum Verständnis der heute gebräuchlichen Zytostatika wichtig, da viele phasenspezifisch wirken, also nur während einer bestimmten Phase des Zellzyklus die Zelle letal schädigen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Allen A (1992) The cardiotoxicity of chemotherapeutic drugs. Semin Oncol 19:529–542PubMedGoogle Scholar
  2. Andus T, Palitzsch K-D, Gross V, Schölmerich J (1993) Metabolische und endokrine Funktionen der Zytokine. Dtsch Med Wochenschr 118:306–313PubMedCrossRefGoogle Scholar
  3. Bellamy WT (1996) P-glycoproteins and multidrug resistance. Annu Pharmacol Toxicol 36:161–183CrossRefGoogle Scholar
  4. Booser DJ, Hortobagyi GN (1994) Anthracycline antibiotics in cancer therapy: Focus on drug resistance. Drugs 47:223–258PubMedCrossRefGoogle Scholar
  5. Brock N, Pohl J, Schneider B (1990) Basic principles i preclinical cancer chmotherapy. J Cancer Res Clin Oncol 116:411–424PubMedCrossRefGoogle Scholar
  6. Burkart C (1994) Das Tumorsuppressorprotein p53. Dtsch Ärztebl 91:B679–B684Google Scholar
  7. Chabner BA, Wilson W (1991) Reversal of multidrug resistance. J Clin Oncol):4–6Google Scholar
  8. Daher GC, Harris BE, Diasio RB (1990) Metabolism of pyrimidine analogues and their nucleosides. Pharmacol Ther 48:189–222PubMedCrossRefGoogle Scholar
  9. De Isabella P, Capranico G, Zunino F (1991) The role of topoisomerase II in drug resistance. Life Sci 48:2195–2205PubMedCrossRefGoogle Scholar
  10. DeSpain JD (1992) Dermatologic toxicity of chemotherapy. Semin Oncol 19:501–507PubMedGoogle Scholar
  11. Drews J (1979) Grundlagen der Chemotherapie. Springer, WienCrossRefGoogle Scholar
  12. Diasio RB, Harris BE (1989) Clinical pharmacology of 5-fluo-rouracil. Clin Pharmacokinet 16:215–237PubMedCrossRefGoogle Scholar
  13. Forbes A, Reading NG (1995) Review article: The risks of malignancy from either immunosuppression or diagnostic radiation in inflammatory bowel disease. Aliment Pharmacol Ther 9:465–470PubMedCrossRefGoogle Scholar
  14. Foye WO (1995) Cancer chemotherapeutic agents. Am Chem Soc Profess Reference BookGoogle Scholar
  15. Fulton B, Markham A (1996) Mycophenolate mofetil: A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. Drugs 51:278–298PubMedCrossRefGoogle Scholar
  16. Gillis JC, Goa KL (1995) Tretinoin: A review of its pharmacodynamic and pharmacokinetic properties and use in the management of acute promyelocytic leukaemia. Drugs 50:897–923PubMedCrossRefGoogle Scholar
  17. Goa KL, Barradell LB (1995) Fluconazole: An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Drugs 50:658–690PubMedCrossRefGoogle Scholar
  18. Gottesman MM, Pastan I (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62:385–427PubMedCrossRefGoogle Scholar
  19. Gräfe, U (1992) Biochemie der Antibiotika: Struktur, Biosynthese, Wirkmechanismus. Spektrum, Heidelberg Berlin New YorkGoogle Scholar
  20. Gratiot-Deans J, Turka LA (1994) New biologic immunosuppressive agents in transplantation. Curr Opin Nephrol Hypertens 3:596–601PubMedCrossRefGoogle Scholar
  21. Grunberg SM, Hesketh PJ (1993) Control of chemotherapy-induced emesis. N Engl J Med 239:1790–1796Google Scholar
  22. Günther I, Drings P (1990) Carboplatin: ein neues Zytostatikum. Arzneimitteltherapie 8:33–38Google Scholar
  23. Harris CC, Hollstein M (1993) clinical implications of the p 53 tumor-suppressor gene. N Engl J Med 329:1318–1327PubMedCrossRefGoogle Scholar
  24. Heidemann H (1992) Onkologie und Hämatologie. 2. Aufl. Urban SchwarzenbergGoogle Scholar
  25. Helderman JH (1995) Review and preview of anti-T-cell antibodies. Transplant Proc 27(Suppl 1):8–9PubMedGoogle Scholar
  26. Henwood JM, BRogden RN (1990) Etoposide: A review of ist pharmacodynamic and pharmacokinetic proterties, and therapeutic potential in combination chemotherapy of cancer. Drugs 39:438–490PubMedCrossRefGoogle Scholar
  27. Herrmann R, Schlag P (Hrsg) (1988) Neoadjuvante Chemotherapie maligner Tumoren. Thieme, StuttgartGoogle Scholar
  28. Hill ADK, Redmond HP, Croke DT, Grace PA, Bouchier-Hayes D (1992) Cytokines in tumour therapy. Br J Surg 79:990–997PubMedCrossRefGoogle Scholar
  29. Höffken K, Schmidt CG, Mertelsmann RH, Herrmann F (1990) Modulation physiologischer Regulationsmechanismen durch Zytokine. Dtsch Ärztebl 87:B2410–B2416Google Scholar
  30. Huhn D, Herrmann R (1990) Medikamentöse Therapie maligner Erkrankungen, 2. Aufl., Fischer, StuttgartGoogle Scholar
  31. Kahan BD, Ghobrial R (1994) Immunosuppressive agents. Surg Clin North Am 74:1029–1054PubMedGoogle Scholar
  32. Keizer HG, Pinedo HM, Schuurhuis GJ, Joenje H (1990) Doxorubicin (Adriamycin): A critical review of free radicaldependent mechanisms of cytoxicity. Pharmacol Ther 47:219–231PubMedCrossRefGoogle Scholar
  33. Kirste G (1996) Mycophenolatmofetil. Arzneimitteltherapie 14:225–226Google Scholar
  34. Kreisman H, Wolkove N (1992) Pulmonary toxicity of antineoplastic therapy. Semin Oncol 19:508–520PubMedGoogle Scholar
  35. Kunz J, Hall MN (1993) Cyclosporin A, FK 506 and rapamyin: More than just immunosuppression. Trends Biochem Sci 18:334–338PubMedCrossRefGoogle Scholar
  36. Laffer U (Hrsg) (1988) Regional chemotherapy: Antibiot Chemother 40, Karger, BaselGoogle Scholar
  37. Lee CR, Faulds D (1995) Altretamine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cancer chemotherapy. Drugs 49:932–953PubMedCrossRefGoogle Scholar
  38. Lennard L (1992) The clinical pharmacology of 6-mercapto-purin. Eur J Clin Pharmacol 43:329–339PubMedCrossRefGoogle Scholar
  39. Libretto SE (1995) Review of the toxicology of beclomethasone dipropionate. Arch Toxicol 69:509–525PubMedCrossRefGoogle Scholar
  40. Loadman PM, Bibby MC (1994) Pharmacokinetic drug interactions with anticancer drugs. Clin Phaarmacokinet 26:486–500CrossRefGoogle Scholar
  41. McCune WJ, Vallance DK, Lynch JP (1994) Immunosuppressive drug therapy. Curr Opin Rheumatol 6:262–272PubMedCrossRefGoogle Scholar
  42. Noble S, Markham A (1995) Cyclosporin: A review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral). Drugs 50:924–941PubMedCrossRefGoogle Scholar
  43. Oldham RK (Hrsg) (1987) Principles of cancer biotherapy. Raven, New YorkGoogle Scholar
  44. Parker WB, Cheng YC (1990) Metabolism and mechanism of action of 5-fluorouracil. Pharmacol Ther 48:381–395PubMedCrossRefGoogle Scholar
  45. Patterson WP, Reams GP (1992) Renal toxicities of chemotherapy. Semin Oncol 19:521–528PubMedGoogle Scholar
  46. Perry MC (1992) Chemotherapeutic agents and hepatotoxicity. Semin Oncol 19:551–565PubMedGoogle Scholar
  47. Pfreundschuh M, Diehl V (1989) Palliative internistische Therapie maligner Erkrankungen. Dtsch Med Wochenschr 114:1797–1803PubMedCrossRefGoogle Scholar
  48. Possinger K (1996) Vinorelbin — neues Vincaalkaloid für die Onkologie. Arzneimitteltherapie 14:227–230Google Scholar
  49. Reichle A, Diddens H, Rastetter J, Berdel WE (1991) Resistenzmechanismen maligner Zellen gegenüber Zytostatika. Dtsch Med Wochenschr 116:186–191PubMedCrossRefGoogle Scholar
  50. Rittmaster RS (1994) Finasteride. N Engl J Med 330:120–125PubMedCrossRefGoogle Scholar
  51. Rohlff C, Glazer RI (1995) Regulation of multidrug resistance through the cAMP and EGF signalling pathways. Cell Signal 7:431–443PubMedCrossRefGoogle Scholar
  52. Rowinsky EK, Donehower RC (1995) Paclitaxel (Taxol). N Engl J Med 332:1004–1014PubMedCrossRefGoogle Scholar
  53. Sauer H (1991) Zytostatikatherapie beim alten Menschen. Internist 32:479–485PubMedGoogle Scholar
  54. Saven A, Piro L (1994) Newer purine analogues for the treatment of hairy-cell leukemia. N Engl J Med 330:691–697PubMedCrossRefGoogle Scholar
  55. Schellens JHM, Pronk LC, Verweij J (1996) Emerging drug treatment for solid tumours. Drugs 51:45–72PubMedCrossRefGoogle Scholar
  56. Schwartsmann G, Workman P (1993) Anticancer drug screening and discovery in the 1990s: A European perspective. Eur J Cancer 29A:3–14CrossRefGoogle Scholar
  57. Thomas FT, Tepper MA, Thomas JM, Haisch CE (1993) 15-Deoxyspergualin: A noval immunosuppressive drug with clinical potential. Ann New York Sci 685:175–192CrossRefGoogle Scholar
  58. Twygcroll RG, Lack SA (1989) Therapie bei Krebs im Endstadium. Fischer, StuttgartGoogle Scholar
  59. Vendrik CPJ, Bergers JJ, De Jong WH, Steerenberg PA (1992) Resistance to cytostatic drugs at the cellular level. Cancer Chemother Pharmacol 29:413–429PubMedCrossRefGoogle Scholar
  60. Volm M, Efferth T (1994) Resistenzüberwindung bei Tumoren. Dtsch Med Wochenschr 119:475–479PubMedCrossRefGoogle Scholar
  61. Walsh CT, Zydowsky LD, McKeon FD (1992) Cyclosporin A, the cyclophilin class of peptidylprolyl isomerase, and blockade of T cell signal transduction. J Biol Chem 267:13115–13118PubMedGoogle Scholar
  62. Wilde MI, Goa KL (1996) Muromonab CD3: A reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection. Drugs 51:865–894PubMedCrossRefGoogle Scholar
  63. Wiseman LR, Markham A (1996) Irinotecan: A review of its pharmacological properties and clinical efficacy in the management of advanded colorectal cancer. Drugs 52:606–623PubMedCrossRefGoogle Scholar
  64. Zeller WJ, zur Hausen H (1995) Onkologie: Grundlagen, Diagnostik, Therapie, Entwicklungen. Ecomed Verlagsges, LandsbergGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1999

Authors and Affiliations

  • E. Oberdisse

There are no affiliations available

Personalised recommendations